Monopar Therapeutics Q2 2024 10-Q Filed
Ticker: MNPR · Form: 10-Q · Filed: 2024-08-09T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, stock-options
TL;DR
**Monopar Q2 10-Q: $17.6M cash, stock options detailed.**
AI Summary
Monopar Therapeutics filed its 10-Q for the period ending June 30, 2024. The company reported cash and cash equivalents of $17,601,827 as of June 30, 2024. The filing details stock option vesting schedules, with 78,592 options subject to specific vesting terms.
Why It Matters
This filing provides investors with an update on Monopar Therapeutics' financial position and operational details for the second quarter of 2024.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Monopar Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- $17.6B — Cash and Cash Equivalents (As of June 30, 2024, indicating liquidity.)
- 78,592 — Stock Options (Subject to vesting, impacting potential future dilution.)
Key Players & Entities
- Monopar Therapeutics (company) — Filer of the 10-Q
- June 30, 2024 (date) — End of reporting period
- $17,601,827 (dollar_amount) — Cash and cash equivalents as of June 30, 2024
- 78,592 (number) — Number of stock options subject to vesting
FAQ
What was Monopar Therapeutics' cash and cash equivalents balance as of June 30, 2024?
Monopar Therapeutics reported cash and cash equivalents of $17,601,827 as of June 30, 2024.
What is the total number of stock options subject to vesting mentioned in the filing?
The filing states that 78,592 options vest according to specific schedules.
What types of investments constitute Monopar's cash equivalents?
Cash equivalents represent the fair value of the Company's investment in two money market accounts and U.S. Treasury Bills with maturities of three months or less.
Were there any forfeitures of stock options during the six months ended June 30, 2024?
No, there were no forfeitures during the six months ended June 30, 2024.
Did Monopar Therapeutics grant any restricted stock units during the three months ended March 31, 2024?
No, there were no restricted stock units granted during the three months ended March 31, 2024.
From the Filing
0001437749-24-025651.txt : 20240809 0001437749-24-025651.hdr.sgml : 20240809 20240809080222 ACCESSION NUMBER: 0001437749-24-025651 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240809 DATE AS OF CHANGE: 20240809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 241190456 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 10-Q 1 mnpr20240630_10q.htm FORM 10-Q mnpr20240630_10q.htm 0001645469 Monopar Therapeutics Inc. false --12-31 Q2 2024 0.001 0.001 40,000,000 40,000,000 17,601,827 17,601,827 14,904,497 14,904,497 81,932 37,661 26,522 17,601,827 0.001 5.0 5.01 10.0 10.01 15.0 15.01 20.0 0 false false false false There were no forfeitures during the six months ended June 30, 2024. 78,592 options vest as follows: options to purchase 10,000 shares of the Company’s common stock vest monthly over one year; options to purchase 68,592 shares of the Company's common stock vest 6/48ths on the six-month anniversary of vesting commencement date and 1/48th per month thereafter. Cash equivalents as of June 30, 2024 and December 31, 2023, represent the fair value of the Company’s investment in two money market accounts and U.S. Treasury Bills with maturities at the date of purchase of three months or less. There were no restricted stock units granted during the three months ended March 31, 2024. Forfeitures only include known forfeitures to-date as the Company accounts for forfeitures as they occur due to a limited history of forfeitures. Investments represents the fair value of the Company’s investment in U.S. Treasury Bills with maturities at the date of purchase over three months to one year. 0001645469 2024-01-01 2024-06-30 xbrli:shares 0001645469 2024-07-31 thunderdome:item iso4217:USD 0001645469 2024-06-30 0001645469 2023-12-31 iso4217:USD xbrli:shares 0001645469 2024-04-01 2024-06-30 0001645469 2023-04-01 2023-06-30 0001645469 2023-01-01 2023-06-30 0001645469 us-gaap:CommonStockMember 2023-12-31 0001645469 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001645469 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001645469 us-gaap:RetainedEarningsMember 2023-12-31 0001645469 2024-01-01 2024-03-31 0001645469 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001645469 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001645469 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001645469 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001645469 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001645469 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001645469 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001645469 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001645469 us-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-01-01 2024-03-31 0001645469 us-gaap:CommonStockMember 2024-03-31 0001645469 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001645469 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001645469 us-gaap:RetainedEarningsMember 2024-03-31 0001645469 2024-03-31 0001645469 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001645469 us-gaap:ShareBasedPaymentArrangementEmployeeMember us-gaap:AdditionalPaidInCapitalMember